1. Search Result
Search Result
Results for "

neurotrophin receptor

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

3

Peptides

1

Inhibitory Antibodies

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-117088
    LM11A-31
    5+ Cited Publications

    Neurokinin Receptor Neurological Disease
    LM11A-31, a non-peptide p75 NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression .
    LM11A-31
  • HY-110155A

    Drug Isomer Neurological Disease
    (Rac)-LM11A-31 dihydrochloride is an isomer of LM11A-31 dihydrochloride. LM11A-31 dihydrochloride, a non-peptide p75 NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist .
    (Rac)-LM11A-31 dihydrochloride
  • HY-110155
    LM11A-31 dihydrochloride
    5+ Cited Publications

    Neurotensin Receptor Neurological Disease
    LM11A-31 dihydrochloride, a non-peptide p75 NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 dihydrochloride is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 dihydrochloride reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression .
    LM11A-31 dihydrochloride
  • HY-104047
    LM22B-10
    Maximum Cited Publications
    17 Publications Verification

    Trk Receptor Akt ERK Neurological Disease
    LM22B-10 is an activator of TrkB/TrkC neurotrophin receptor, and can induce TrkB, TrkC, AKT and ERK activation in vitro and in vivo.
    LM22B-10
  • HY-152472

    Trk Receptor Neurological Disease
    ENT-C225 is an effective activator of TrkB neurotrophin receptor. ENT-C225 has high effect on activating TrkB receptor (TrkBR), and has good physicochemical properties and neuroprotective properties .
    ENT-C225
  • HY-137322

    Neurotensin Receptor Neurological Disease Metabolic Disease
    THX-B is a potent and non-peptidic p75 NTR (neurotrophin receptor p75) antagonist. THX-B can be used in the research of diabetic kidney disease, neurodegenerative and inflammatory disorders .
    THX-B
  • HY-P99297

    ZTS-00508841

    Trk Receptor Inflammation/Immunology
    Bedinvetmab (ZTS-00508841) is a canine monoclonal antibody (mAb) targeting nerve growth factor (NGF). Bedinvetmab inhibits NGF interaction with tropomyosin receptor kinase A (trkA) and p75 neurotrophin receptor (p75NTR) receptors. Bedinvetmab can be used for the research of osteoarthritis pain in dogs .
    Bedinvetmab
  • HY-146523

    Trk Receptor Cancer
    TRK-IN-17 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-17 has the potential for the research of cancer diseases (extracted from patent WO2021148807A1, compound 3) .
    TRK-IN-17
  • HY-146524

    Trk Receptor Cancer
    TRK-IN-18 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-18 has the potential for the research of cancer diseases (extracted from patent WO2021148805A1, compound 7) .
    TRK-IN-18
  • HY-P1176

    Apoptosis Neurological Disease
    NTR 368 is a peptide derived from p75 neurotrophin receptor (p75NTR) corresponding to residues 368-381 of the human receptor. NTR 368 has helix forming propensity in the presence of micellar lipid. NTR 368 is a potent inducer of neural apoptosis .
    NTR 368
  • HY-P1176A

    Apoptosis Neurological Disease
    NTR 368 TFA is a peptide derived from p75 neurotrophin receptor (p75NTR) corresponding to residues 368-381 of the human receptor. NTR 368 TFA has helix forming propensity in the presence of micellar lipid. NTR 368 TFA is a potent inducer of neural apoptosis .
    NTR 368 TFA
  • HY-W370556

    Neurokinin Receptor Neurological Disease
    (Rac)-LM11A-31 is a racemate of LM11A-31. LM11A-31 is a non-peptide modulator of p75NTR (neurotrophin receptor p75) and is an orally effective proNGF antagonist .
    (Rac)-LM11A-31
  • HY-111163

    Apoptosis Cancer
    NSC49652 is a reversible, orally active p75 neurotrophin receptor (p75 NTR, also known as NGFR, TNFRSF16, and CD271) agonist. NSC49652 targets the transmembrane domain of p75 NTR. NSC49652 induces apoptosis and affects the viability of melanoma cells .
    NSC49652
  • HY-P4486

    Drug Derivative Others
    H-Pro-Gly-Pro-OH is a collagen-derived matrikine that has classically been described as a neutrophil chemoattractant. H-Pro-Gly-Pro-OH is perfectly positioned to focus neutrophils on the site required and direct a localized repair response. H-Pro-Gly-Pro-OH activates the transcription of neurotrophins and their receptor genes after cerebral ischemia .
    H-Pro-Gly-Pro-OH

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: